kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant SARS-CoV-2 (COVID-19) S1 protein (N501Y), His Tag, 1mg (4x 250µg)  

Recombinant SARS-CoV-2 (COVID-19) S1 protein (N501Y), His Tag, 1mg (4x 250µg)

Recombinant SARS-CoV-2 (COVID-19) S1 protein (N501Y), AA Val 16 - Arg 685, expressed from human 293 cells (HEK293), His-Tag

Synonyms: Recombinant, Spike, S1 protein, Spike glycoprotein Subunit1, S glycoprotein Subunit1, Spike protein S1

More details


Availability: within 10-14 days

2 540,00 €

IIt's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Recombinant SARS-CoV-2 S1 protein (N501Y), His Tag (S1N-C52Hg) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Arg 685 (Accession # QHD43416.1(N501Y)). N501Y mutaion was identified in both the SARS-CoV-2 variant (known as 20B/501Y.V1, VOC 202012/01, or B.1.1.7 lineage) which emerged in the United Kindom and SARS-CoV-2 variant (known as 20C/501Y.V2 or B.1.351 lineage) which emerged in South Africa.
Predicted N-terminus: Val 16

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 76.9 kDa. The protein migrates as 110-130 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg by the LAL method.

>90% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally trehalose is added as protectant before lyophilization.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "Decline of antibody titres three months after two doses of BNT162b2 in non-immunocompromised adults"
Erice, Varillas-Delgado, Caballero
Clin Microbiol Infect (2021)
(2) "SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis"
Bensouna, Caudwell, Kubab et al
Am J Kidney Dis (2021)
(3) "Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines"
Wisnewski, Redlich, Liu et al
PLoS One (2021) 16 (9), e0252849
Showing 1-3 of 1333 papers.
Please refer to product data sheet.